Table 2.

Primary and secondary outcomes at 6 months in the CaRISMA trial

OutcomeEstimated 6-month changeCBT vs EducationCohen d
CBTEducation
Primary     
Pain interference (PROMIS-8a) −2.13 (−3.42 to −0.84) −2.66 (−3.97 to −1.36) 0.54 (−1.30 to 2.37)
P = .57 
0.06 (−0.15 to 0.27) 
Secondary     
Average daily pain intensity 0.20 (−0.18 to 0.58) 0.13 (−0.25 to 0.51) 0.07 (−0.46 to 0.61)
P = .79 
0.05 (−0.37 to 0.49) 
PHQ  −1.33 (−2.28 to −0.39) −1.12 (−2.06 to −0.18) −0.21 (−1.55 to 1.12)
P = .75 
0.04 (−0.27 to 0.19) 
GAD-7  −0.85 (−1.68 to −0.01) −1.49 (−2.40 to −0.58) 0.64 (−0.60 to 1.87)
P = .31 
0.13 (−0.12 to 0.37) 
ASCQ-Me: social functioning 2.45 (1.13-3.76) 2.34 (1.00-3.68) 0.11 (−1.77 to 1.99)
P = .91 
0.01 (−0.19 to 0.22) 
ASCQ-Me: emotional impact 3.51 (2.29-4.73) 1.79 (0.55-3.04) 1.72 (−0.03 to 3.46)
P = .05 
0.20 (−0.004 to 0.41) 
SCSES 1.45 (0.44-2.46) 0.32 (−0.70 to 1.35) 1.13 (−0.31 to 2.56)
P = .12 
0.16 (−0.04 to 0.37) 
OutcomeEstimated 6-month changeCBT vs EducationCohen d
CBTEducation
Primary     
Pain interference (PROMIS-8a) −2.13 (−3.42 to −0.84) −2.66 (−3.97 to −1.36) 0.54 (−1.30 to 2.37)
P = .57 
0.06 (−0.15 to 0.27) 
Secondary     
Average daily pain intensity 0.20 (−0.18 to 0.58) 0.13 (−0.25 to 0.51) 0.07 (−0.46 to 0.61)
P = .79 
0.05 (−0.37 to 0.49) 
PHQ  −1.33 (−2.28 to −0.39) −1.12 (−2.06 to −0.18) −0.21 (−1.55 to 1.12)
P = .75 
0.04 (−0.27 to 0.19) 
GAD-7  −0.85 (−1.68 to −0.01) −1.49 (−2.40 to −0.58) 0.64 (−0.60 to 1.87)
P = .31 
0.13 (−0.12 to 0.37) 
ASCQ-Me: social functioning 2.45 (1.13-3.76) 2.34 (1.00-3.68) 0.11 (−1.77 to 1.99)
P = .91 
0.01 (−0.19 to 0.22) 
ASCQ-Me: emotional impact 3.51 (2.29-4.73) 1.79 (0.55-3.04) 1.72 (−0.03 to 3.46)
P = .05 
0.20 (−0.004 to 0.41) 
SCSES 1.45 (0.44-2.46) 0.32 (−0.70 to 1.35) 1.13 (−0.31 to 2.56)
P = .12 
0.16 (−0.04 to 0.37) 

PHQ-9 for clinic participants and PHQ-8 for virtual participants with baseline PHQ-2 >0.

GAD-7 for all participants with baseline GAD-2 >0.

Close Modal

or Create an Account

Close Modal
Close Modal